Mannkind Corp Stock Today
| MNKD Stock | USD 4.10 0.17 4.33% |
PerformanceVery Weak
| Odds Of DistressVery Small
|
MannKind Corp is trading at 4.10 as of the 24th of July 2025, a 4.33% increase since the beginning of the trading day. The stock's lowest day price was 3.89. MannKind Corp has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 25th of April 2025 and ending today, the 24th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of July 2004 | Category Healthcare | Classification Health Care |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. The company has 303.93 M outstanding shares of which 25.15 M shares are now shorted by private and institutional investors with about 7.65 trading days to cover. More on MannKind Corp
Moving against MannKind Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
MannKind Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | David Thomson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Mannkind Corp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMannKind Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MannKind Corp's financial leverage. It provides some insight into what part of MannKind Corp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MannKind Corp (MNKD) is traded on NASDAQ Exchange in USA. It is located in 1 Casper Street, Danbury, CT, United States, 06810 and employs 403 people. MannKind Corp is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.19 B. MannKind Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 303.93 M outstanding shares of which 25.15 M shares are now shorted by private and institutional investors with about 7.65 trading days to cover.
MannKind Corp currently holds about 154.16 M in cash with 42.51 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check MannKind Corp Probability Of Bankruptcy
Ownership AllocationMannKind Corp maintains a total of 303.93 Million outstanding shares. Over half of MannKind Corp's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MannKind Ownership Details
MannKind Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2025-03-31 | 3.7 M | |
| Dimensional Fund Advisors, Inc. | 2025-03-31 | 3.5 M | |
| Nuveen, Llc | 2025-03-31 | 3.4 M | |
| Two Sigma Investments Llc | 2025-03-31 | 3.4 M | |
| Qube Research & Technologies | 2025-03-31 | 3.2 M | |
| Tsp Capital Management Group/llc | 2025-03-31 | 2.8 M | |
| Arrowstreet Capital Limited Partnership | 2025-03-31 | 2.7 M | |
| Northern Trust Corp | 2025-03-31 | 2.7 M | |
| Parkman Healthcare Partners Llc | 2025-03-31 | 2.5 M | |
| Blackrock Inc | 2025-03-31 | 24.5 M | |
| Vanguard Group Inc | 2025-03-31 | 17.3 M |
MannKind Corp Historical Income Statement
MannKind Stock Against Markets
MannKind Corp Corporate Management
| John Bedard | Senior Affairs | Profile | |
| Burkhard MD | Executive Officer | Profile | |
| Stuart Tross | Chief People Officer | Profile | |
| Christopher MBA | Chief Officer | Profile | |
| Lauren Sabella | Executive Operations | Profile | |
| Michael PharmD | CEO Director | Profile | |
| McCauley JD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MannKind Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade MannKind Stock refer to our How to Trade MannKind Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MannKind Corp. If investors know MannKind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MannKind Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.089 | Earnings Share 0.1 | Revenue Per Share | Quarterly Revenue Growth 0.182 | Return On Assets |
The market value of MannKind Corp is measured differently than its book value, which is the value of MannKind that is recorded on the company's balance sheet. Investors also form their own opinion of MannKind Corp's value that differs from its market value or its book value, called intrinsic value, which is MannKind Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MannKind Corp's market value can be influenced by many factors that don't directly affect MannKind Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MannKind Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if MannKind Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MannKind Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.